Download in protein-based therapeutics and technologies

SØREN BREGENHOLT
Corporate Vice President
Denmark
BARBARA ARANEO
Innovation Sourcing Director
USA
MARTIN E. JUDGE
Innovation Sourcing Directorr
Denmark
CHUCK GRAY
Innovation Sourcing Director
USA
ANAND GAUTAM
Innovation Sourcing Director
Denmark
ANAND GAUTAM
Innovation scouting director
Denmark
IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES
TOMAS LANDH
Senior Principal Scientist
Denmark
JØRN ROLAND MÜLLER
Innovation Sourcing Director
Denmark
Partnering
for
innovation
Novo Nordisk is seeking potential partners who can help
us to improve patient therapy by discovering innovative
peptide- and protein-based therapeutics for treatment of
• DIABETES
• OBESITY
• DIABETIC LATE COMPLICATIONS
• PROTEIN TECHNOLOGIES
• HAEMOPHILIA
Discover more about Partnering for innovation at http://www.novonordisk.com/rnd/partnering
MARTIN
[email protected]
+45 30797988
CHUCK
[email protected]
+1 8453237463
TOMAS
[email protected]
+45 30757115
ANAND
[email protected]
+45 30797971
Looking for
Diabetes
JØRN
[email protected]
+45 30751988
For more information about Novo Nordisk, visit
novonordisk.com
Or follow us on
BARBARA
[email protected]
+1 2064738289
Insulin and GLP-1 receptor peptide-agonists:
• Insulins and GLP-1s with novel therapeutic properties
o Optimised for oral delivery
o Modified duration of action
o Improved side-effect profile
Therapeutic proteins and peptides affecting:
• Glucose regulation
o With anti-obesity effects, and/or
anti-hyperlipidaemia, and/or
anti-atherosclerotic effects
o Without inducing hypoglycaemia, and/or
inducing weight gain
• Insulin secretion
• Insulin resistance
• Beta-cell mass
• Inflammation related to diabetes and obesity
• Prevention/progression of diabetes
Obesity
Protein peptides for obesity treatment:
• Addressing comorbidities
• Affecting e.g.
o Appetite regulation
o Energy expenditure
Haemophilia
• Longer duration of action of coagulation factors
• Novel bypassing principles
• Tolerance and immunogenicity
• Joint health
Human growth hormone disorders
• Longer duration of action of hGH
• Oral delivery
Diabetic late complications
o
o
• Novel biologics to treat microvascular complications:
o Diabetic retinopathy
o Diabetic nephropathy
New protein delivery devices
• Injection of soluble protein formulations
• Reconstitution and infusion of lyophilised protein formulations
Protein technologies
Protein and peptide technologies:
• Expression
• Modification
• Production
Formulation and delivery technologies:
• Liquid
• Oral
• Sustained/triggered release